LABU - Direxion Daily S&P Biotech Bull 3x Shares
|Ex-Dividend Date||Dec 23, 2019|
|Trading Day||April 21|
|Day's Range||63.70 - 65.79|
|52-Week Range||32.20 - 185.61|
The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Biotechnology Select Industry Index (index). The fund invests at least 80% of its net assets (plus borrowing for investment purposes) in financial instruments and securities of the index, exchange-traded funds (ETFs) that track the index and other financial instruments that provide daily leveraged exposure to the index or ETFs that track the index. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). The fund is non-diversified.
|Asset Class |
|Inception Date |
May 28, 2015
|Ticker Symbol |
|Index Tracked |
S&P Biotechnology Select Industry Index
Top 10 Holdings76.51% of assets
|S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP||n/a||31.21%|
|S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP||n/a||11.60%|
|S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP||n/a||10.71%|
|S&P Biotechnology Select Industry Index SWAP||n/a||6.99%|
|S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP||n/a||5.84%|
|DREYFUS GOVT CASH MGMT||n/a||2.96%|
|DREYFUS GOVT CASH MGMT||n/a||2.74%|
|GOLDMAN FINL SQ TRSRY INST 506||n/a||1.57%|
|DREYFUS GOVT CASH MGMT||n/a||1.56%|
|GOLDMAN FINL SQ TRSRY INS||n/a||1.33%|
|Dec 23, 2019||$0.005||Dec 31, 2019|
|Sep 24, 2019||$0.011||Oct 1, 2019|
|Jun 25, 2019||$0.037||Jul 2, 2019|
|Mar 19, 2019||$0.11||Mar 26, 2019|
|Dec 27, 2018||$0.096||Jan 4, 2019|
|Sep 25, 2018||$0.095||Oct 2, 2018|
Direxion's weekly ETF fund flows could shed light on what traders are thinking. The top three point to interest in long-term bond prices, biotech strength, and semiconductor weakness.
U.S. president Joe Biden's infrastructure plan is opening up ETF trading possibilities from multiple angles. One way is playing its healthcare component via funds like the Direxion Daily Healthcare Bull...
The biotechnology industry isn't backing down, with ETFs like the Direxion Daily S&P Biotech Bull 3x Shares (LABU) gaining over 15% to start the new year. More strength could be ahead as the global econ...
We highlight some leveraged ETFs that gained more than 85% over the past three months.
Traders understand that when you add leverage to the mix, the results can be explosive gains, but on the flip side, it could be losses and a blown trading account. Yahoo Finance focused on top leveraged...
The S&P 500, the Dow Jones and the Nasdaq Composite gained about 1.7%, 1.0% and 2.1%, respectively, last week.
The solid fundamentals and a soaring stock market have resulted in huge demand for the leveraged ETFs.
The Covid-19 brought certain sectors serendipitous gains like technology, but even that space is now seeing sell-offs amid a September sell-off. As such, short sellers are coming in to reap the rewards,...
It’s been a memorable, if not unusual, summer of 2020, but it’s not stopping biotech bulls from charging forward. The sector has been on a steady uptrend despite the economic effects of Covid-19.
LABU: Which Biotechs Have Led the Covid Trade? Summertime is typically regarded as a notoriously choppy month for markets as volume tends to dissipate.
As the broad market knocks on the door of all-time highs in the midst of a still-raging public health crisis, traders have had to simultaneously ride the bullish wave (in most sectors) while also modera...
The coronavirus pandemic is fueling gains for biotechnology exchange traded funds this year and the leverage members of this group are participating in the fun.
After a brutal first quarter, U.S. stocks strongly rebounded on an unprecedented fiscal and monetary stimulus, progress in the development of a coronavirus vaccine or treatment as well as optimism over ...
U.S. stocks came back roaring in April buoyed by unprecedented fiscal and monetary stimulus, progress in the development of a coronavirus vaccine or treatment as well as optimism over the reopening of t...
The biotech and healthcare space has been on fire lately. The healthcare space is witnessing a Mergers and Acquisitions wave recently that has achieved an impressive $342 billion in new deal activity so...
Jablonski: Biotech presents a good buying opportunity
Sylvia Jablonski of Direxion discusses why biotech stocks and ETFs are attractive right now, due to their cheapness relative to the rest of the market.
The U.S.-China trade war is more than 18 months old. And in that time the conflict has taken a toll on stocks across the world and put company executives and market watchers alike on edge.
Biotech stocks fall after Trump promises executive order drug prices
CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.
With biotechnology stocks and the related exchange-traded funds recently showing some signs of life, it could be just a matter of time before aggressive traders embraced leveraged healthcare ETFs.
When the stock market is hitting record highs, it’s important to remember that it’s really a market of stocks rather than a stock market. Not all companies are created equal. Nor are all sectors.
Leveraged biotechnology exchange traded funds (ETFs) are known to make big moves, but sometimes those moves are not always about price action.